Investment Analysts’ Weekly Ratings Changes for Monte Rosa Therapeutics (GLUE)

Several brokerages have updated their recommendations and price targets on shares of Monte Rosa Therapeutics (NASDAQ: GLUE) in the last few weeks:

• 10/5/2026 – Monte Rosa Therapeutics was given a new $25.00 price target by Raymond James Financial, Inc..
• 10/5/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by Benchmark Co..
• 10/1/2026 – Monte Rosa Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 10/1/2026 – Monte Rosa Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 9/9/2026 – Monte Rosa Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $27.00 price target on the stock.
• 8/25/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $28.00 price target on the stock.
• 8/24/2026 – Monte Rosa Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/11/2026 – Monte Rosa Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.